Diversified Trust Co. Acquires 7,155 Shares of Thermo Fisher Scientific Inc. $TMO

Key Points

• Diversified Trust Co. increased its Thermo Fisher Scientific stake by 71.1% in the second quarter, purchasing 7,155 shares and bringing its holdings to 17,214 shares valued at approximately $8.63 million. Institutional investors collectively own 89.23% of TMO.
• Thermo Fisher reported stronger-than-expected quarterly results, with EPS of $6.03 and revenue of $11.99 billion; revenue rose 10.5% year over year. The company reaffirmed fiscal 2026 EPS guidance of $24.93–$25.33.
• Analysts maintain a generally positive view, with a “Moderate Buy” consensus and an average price target of $619.41. The company also declared a quarterly dividend of $0.47 per share, while insiders have sold 52,053 shares worth about $30.6 million over the past three months.

Diversified Trust Co. raised its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 71.1% in the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 17,214 shares of the medical research company's stock after buying an additional 7,155 shares during the quarter. Diversified Trust Co.'s holdings in Thermo Fisher Scientific were worth $8,630,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Vanguard Group Inc. lifted its position in Thermo Fisher Scientific by 0.9% during the fourth quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock valued at $19,778,774,000 after purchasing an additional 288,296 shares during the last quarter. J. Stern & Co. LLP increased its holdings in shares of Thermo Fisher Scientific by 58,006.4% in the 4th quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock worth $18,258,082,000 after buying an additional 31,455,105 shares during the last quarter. State Street Corp raised its position in shares of Thermo Fisher Scientific by 1.4% during the 4th quarter. State Street Corp now owns 16,613,761 shares of the medical research company's stock valued at $9,633,991,000 after buying an additional 229,630 shares in the last quarter. Capital World Investors lifted its holdings in shares of Thermo Fisher Scientific by 7.0% during the 4th quarter. Capital World Investors now owns 11,003,814 shares of the medical research company's stock worth $6,376,229,000 after acquiring an additional 718,669 shares during the last quarter. Finally, Geode Capital Management LLC grew its position in Thermo Fisher Scientific by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 8,196,477 shares of the medical research company's stock worth $4,728,129,000 after acquiring an additional 26,425 shares in the last quarter. Hedge funds and other institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Down 0.0%

Shares of NYSE:TMO opened at $588.17 on Monday. The stock has a market capitalization of $217.48 billion, a P/E ratio of 31.64, a price-to-earnings-growth ratio of 2.39 and a beta of 0.84. The stock's 50-day moving average price is $529.37 and its 200-day moving average price is $508.75. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12-month low of $435.27 and a 12-month high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share for the quarter, beating analysts' consensus estimates of $5.71 by $0.32. The company had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.Thermo Fisher Scientific's revenue for the quarter was up 10.5% on a year-over-year basis. During the same quarter in the previous year, the company posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. On average, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio is 10.11%.

Analysts Set New Price Targets

A number of equities research analysts have weighed in on TMO shares. Jefferies Financial Group restated a "buy" rating and set a $630.00 price target on shares of Thermo Fisher Scientific in a research report on Thursday, July 23rd. Stifel Nicolaus set a $650.00 price objective on Thermo Fisher Scientific in a research report on Wednesday, August 5th. Wells Fargo & Company decreased their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an "overweight" rating on the stock in a report on Friday, May 8th. Royal Bank Of Canada upped their target price on Thermo Fisher Scientific from $490.00 to $580.00 and gave the stock a "sector perform" rating in a research note on Friday, July 24th. Finally, KeyCorp reiterated an "overweight" rating on shares of Thermo Fisher Scientific in a research report on Tuesday, May 26th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $619.41.

Insider Transactions at Thermo Fisher Scientific

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction on Thursday, August 6th. The shares were sold at an average price of $574.47, for a total value of $5,744,700.00. Following the transaction, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $71,191,194.75. The trade was a 7.47% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of the company's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total transaction of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares of the company's stock, valued at $1,734,546.46. This represents a 12.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 52,053 shares of company stock valued at $30,643,589. 0.33% of the stock is currently owned by insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source